Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Sign Up to like & getrecommendations! Published in 2022 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehac374
Abstract: Abstract Aims In a retrospective analysis of dal-Outcomes, the effect of dalcetrapib on cardiovascular events was influenced by an adenylate cyclase type 9 (ADCY9) gene polymorphism. The dal-GenE study was conducted to test this pharmacogenetic… read more here.
Keywords: primary endpoint; dal gene; trial; dalcetrapib ... See more keywords
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapib.
Sign Up to like & getrecommendations! Published in 2025 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwaf661
Abstract: BACKGROUND Acute coronary syndrome (ACS) survivors have heightened risk for subsequent cardiovascular events. METHODS All baseline characteristics collected in both the Dal-Outcomes and Dal-GenE trials were considered as potential risk markers. A prediction index for… read more here.
Keywords: history; acute coronary; dal gene; index ... See more keywords